We found that blocking the Aplnr during obesity reduces tumour growth likely by affecting tumour microenvironment thereby highlighting that apelinergic system interference could be an interesting therapeutic strategy in the context of obesity and TNBC. Here, APLNR is linked to obesity due to melanocortin 4 receptor deficiency.